Biogen Inc. (BIIB)
NASDAQ: BIIB
· Real-Time Price · USD
123.38
2.45 (2.03%)
At close: May 02, 2025, 3:59 PM
123.55
0.14%
After-hours: May 02, 2025, 05:18 PM EDT
2.03% (1D)
| Bid | 120.1 |
| Market Cap | 18.08B |
| Revenue (ttm) | 9.7B |
| Net Income (ttm) | 1.48B |
| EPS (ttm) | 10.12 |
| PE Ratio (ttm) | 12.19 |
| Forward PE | 7.69 |
| Analyst | Hold |
| Ask | 124.05 |
| Volume | 1,120,345 |
| Avg. Volume (20D) | 1,752,735 |
| Open | 122.83 |
| Previous Close | 120.93 |
| Day's Range | 120.91 - 123.72 |
| 52-Week Range | 110.04 - 238.00 |
| Beta | 0.06 |
About BIIB
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an ad...
Industry Drug Manufacturers - General
Sector Healthcare
IPO Date Sep 17, 1991
Employees 7,605
Stock Exchange NASDAQ
Ticker Symbol BIIB
Website https://www.biogen.com
Analyst Forecast
According to 27 analyst ratings, the average rating for BIIB stock is "Hold." The 12-month stock price forecast is $199, which is an increase of 61.29% from the latest price.
Stock ForecastsEarnings Surprise
Biogen has released their quartely earnings
on May 1, 2025:
2 months ago
-4.28%
Biogen shares are trading lower after the company ...
Unlock content with
Pro Subscription
5 months ago
-1.28%
Biogen shares are trading lower after Needham downgraded the stock from Buy to Hold.
